Clinical trials: Macular Pigment
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Background: Age-related macular degeneration (AMD) is an eye disease. It is the leading cause of vision loss in people over 55 in the U.S. Changes in the eye can make it difficult for they eye to adjust to low light.
- Trial name
- NCT03478878
- Testing
- Vitamin A Palmitate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Eye Institute (NEI)
Dry Macular Degeneration, Geographic Atrophy
Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD
The Phase I/IIa clinical trial is designed to assess the feasibility of delivery and safety of Human Embryonic Stem Cell-Derived RPE Cells on a parylene membrane (CPCB-RPE1) in patients with advanced, dry age-related macular…
- Trial name
- NCT02590692
- Testing
- CPCB-RPE1
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Regenerative Patch Technologies, LLC
Macular Degeneration
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
This study will explore whether taking the vitamins lutein and zeaxanthin, with or without Omega-3 fatty acid (fish oil or docosahexanoic acid, also known as DHA) will change the amount of lutein and zeaxanthin in the blood among…
- Trial name
- NCT00121589
- Testing
- Lutein
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Glaucoma, Open-Angle
European Nutrition in Glaucoma Management Trial
European Nutrition in Glaucoma Management (ENIGMA) trial will evaluate the effect of 18-month supplementation with lutein, zeaxanthin and meso-zeaxanthin on macular pigment (MP) levels, vision, cognition and serum biomarkers of…
- Trial name
- ENIGMA (NCT04460365)
- Testing
- 10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin
- Where
- Ireland
- Volunteers
- 64 people
- Sponsor
- Centre for Eye Research Ireland
Dry Age-Related Macular Degeneration, Geographic Atrophy
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots.
- Trial name
- NCT04339764
- Testing
- iPSC-derived RPE/PLGA transplantation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
High Myopia
Relationships Between Macular Pigment Optical Density and Lacquer Cracks in High Myopic Patients.
Lutein ans zeaxanthin, carotenoids provided by dietary intake are mainly located in the macular area. Its absorption peak at 460 nm may reduce photic damages. The macular pigment density can be evaluated by its optical density.
- Trial name
- NCT02205632
- Testing
- MPS II
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Poitiers University Hospital
Age Related Maculopathy
The Role of Macular Pigment in Patients With Age-related Macular Degeneration
In the industrialised world age-related macular degeneration (ARMD) is the leading cause for legal blindness beyond the age of 50 years.
- Trial name
- NCT00494325
- Where
- Switzerland
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Macular Degeneration, Age-Related Macular Degeneration
The Focal Electro-Oculogram in Macular Disease
Background: Maculopathies are eye conditions that affect the center of the retina. Retina health depends on the retinal pigment epithelium (RPE), a layer behind the retina.
- Trial name
- NCT02225119
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Eye Institute (NEI)
Age Related Macular Degeneration, Macular Degeneration
Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation
Early Phase I Study of the Safety and Preliminary Efficacy of Human Fetal Retinal Pigment Epithelial(fRPE) Cells Subretinal Transplantation in Age-Related Macular Degeneration(AMD) Patients
- Conditions
- Age Related Macular Degeneration, Macular Degeneration, AMD
- Trial name
- NCT02868424
- Testing
- fRPE cells
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Raman Spectroscopy
Raman Scattering Spectroscopy to Measure Macular Pigment
This study will evaluate the ease and reliability of Raman scattering spectroscopy, a new technique to measure the amount of the pigment lutein in the retina, the light-sensitive tissue lining the back of the eye.
- Trial name
- NCT00060580
- Testing
- Raman scattering spectroscopy
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Nonexudative Age-related Macular Degeneration
Directional Spread in Geographic Atrophy
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial countries. In the late stages of the disease, neovascular changes or the development of geographic atrophy (GA) may induce severe…
- Trial name
- DSGA (NCT02051998)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- University Hospital, Bonn
Geographic Atrophy, Age-Related Macular Degeneration
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration.
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration, AMD
- Trial name
- NCT00306488
- Testing
- OT-551 antioxidant eye drop
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Dry AMD With Macular Drusen
Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation
The objective of this study is to determine the repeatability and reproducibility of the Cirrus HD-OCT measurements of drusen area and volume.
- Trial name
- NCT01890174
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Carl Zeiss Meditec, Inc.
Drusen Stage Macular Degeneration
Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography
The objective of this study is to compare the areas designated as elevated retinal pigment epithelium (RPE) by the Cirrus HD-OCT versus those designated as drusen on color fundus photographs (CFPs).
- Trial name
- NCT01272063
- Where
- 4 sites in United States
- Volunteers
- 91 people
- Sponsor
- Carl Zeiss Meditec, Inc.
Epiretinal Membrane, Dry Age Related Macular Degeneration
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
- Conditions
- Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
- Trial name
- NCT07680244
- Testing
- PathFinder 1.0 on CIRRUS HD-OCT
- Where
- 6 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe
Age Related Macular Degeneration (AMD)
Production of iPSC Derived RPE Cells for Transplantation in AMD
No treatments exist for Age-related Macular Degeneration (AMD) when there is cell loss such as in late wet AMD or dry AMD. The differentiation of RPE cells from patient derived iPSC will offer valuable source of tissue for…
- Trial name
- NCT02464956
- Volunteers
- 3 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline.
- Trial name
- NCT01666236
- Testing
- Triple Therapy
- Where
- Brazil
- Sponsor
- Federal University of São Paulo
Presence of Retinal Fluid, Changes in Macular Pigment Optical Density
Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes
Neovascular age-related macular degeneration (nAMD) is one of the main causes of irreversible vision loss in older people worldwide.
- Trial name
- NCT07074054
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Federico II University
Vitiligo - Macular Depigmentation
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation.
- Trial name
- NCT07016113
- Testing
- 0.005% latanoprost gel, 0.1% mometasone furoate cream
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Universitas Padjadjaran
Intermediate AMD
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect.
- Trial name
- retinaSEES-PoC (NCT06557369)
- Testing
- reSEES
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Oculox Technologies SA